Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab ± Lenalidomide plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

被引：0

作者：

Belada, David ^{[1
,2
]}

Kopeckova, Katerina ^{[3
,4
]}

Burgues, Juan Miguel Bergua ^{[5
]}

Stevens, Don ^{[6
]}

Nowakowski, Grzegorz S. ^{[7
]}

Waldron-Lynch, Maeve ^{[8
]}

Hadar, Nira ^{[8
]}

Weirather, Johannes ^{[9
]}

Laessig, Charlotte ^{[9
]}

Blair, Derek ^{[9
]}

Dreyling, Martin ^{[10
]}

机构：

[1] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[2] Fac Med, Hradec Kralove, Czech Republic

[3] Charles Univ Prague, Dept Oncol, Fac Med 2, Prague, Czech Republic

[4] Motol Univ Hosp, Prague, Czech Republic

[5] Hosp San Pedro Alcantara, Dept Hematol, Caceres, Spain

[6] Norton Canc Inst, St Matthews Campus,3991 Dutchmans Lane, Louisville, KY 40207 USA

[7] Mayo Clin, Div Hematol, Rochester, MN USA

[8] MorphoSys US Inc, Boston, MA USA

[9] MorphoSys AG, Planegg, Germany

[10] Ludwig Maximilians Univ Hosp, Univ Clin, Med Clin III, Munich, Germany

来源：

关键词：

ABCL; tafasitamab; lenalidomide; DLBCL; First-MIND; pharmacokinetics; Phase I;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-023

引用

页码：S352 / S352

页数：1